This result was further confirmed by another study showing that MGMT methylation was significantly associated with a longer PFS and OS in prospectively collected grade II gliomas treated with radiotherapy combined with temozolomide (25), suggesting that MGMT methylation may be a better prognostic biomarker in IDH-mutant LGGs. Here, IDH1 is linked to central nervous system cancer.